| [1] |
Thomassen I, van Gestel YR, van Ramshorst B, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors[J]. Int J Cancer, 2014, 134(3): 62 2-8.
|
| [2] |
Yonemura Y, Endou Y, Sasaki T, et al. Surgical treatment for peritoneal carcinomatosis from gastric cancer[J]. Eur J Surg Oncol, 2010, 36(12): 1131-8.
|
| [3] |
Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma[J]. Br J Surg, 2000, 87(2): 236-42.
|
| [4] |
Yang D, Hendifar A, Lenz C, et al. Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity[J]. J Gastrointest Oncol, 2011, 2(2): 77-84.
|
| [5] |
Yang QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies[J]. Gan To Kagaku Ryoho, 2006, 33(12): 1817-21.
|
| [6] |
Mori T, Fujiwara Y, Yano M, et al. Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil[J]. Oncology, 2003, 64(2): 17 6-82.
|
| [7] |
Osugi H, Takada N, Takemura M, et al. Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination[J]. Oncol Rep, 2002,9(4): 811-5.
|
| [8] |
Emi Y, Yamamoto M, Takahashi I, et al. Phase Ⅱstudy of weekly paclitaxel by one-hour infusion for advanced gastric cancer[J]. Surg Today, 2008, 38(11): 1013-20.
|
| [9] |
Kobayashi M, Sakamoto J, Namikawa T, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients[J]. World J Gastroenterol, 2006, 12(9): 1412-5.
|
| [10] |
Ueda Y, Yamagishi H, Ichikawa D, et al. Multicenter phase Ⅱ study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer[J]. Gastric Cancer, 2010, 13 (3): 149-54.
|
| [11] |
Wang X, Wang ML, Zhou LY, et al. Randomized phase Ⅱ study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer[J]. Clin Transl Oncol, 2013, 15 (10): 836-42.
|
| [12] |
Ishigami H, Kitayama J, Kaisaki S, et al. Phase Ⅱ study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis[J]. Ann Oncol, 2010, 21(1): 67-70.
|
| [13] |
Yamaguchi H, Kitayama J, Ishigami H, et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis [J] Cancer, 2013,119(18): 3354-8.
|
| [14] |
Imano M, Yasuda A, Itoh T, et al. Phase Ⅱ study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis[J]. J Gastrointest Surg, 2012, 16(12): 2190-6.
|
| [15] |
Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (spirits trial): a phase Ⅲ trial[J]. Lancet Oncol, 2008, 9(3): 215-21.
|
| [16] |
Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (start)[J]. J Cancer Res Clin Oncol, 2014, 140(2): 319-28.
|
| [17] |
Iwase H, Shimada M, Tsuzuki T, et al. A phase Ⅱ multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer[J]. Oncology, 2011, 80(1-2): 76-83.
|
| [18] |
Shirao K, Boku N, Yamada Y, et al. Randomized phase Ⅲ study of 5-fluorouracil continuous infusion vs. Sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106)[J]. Jpn J Clin Oncol, 2013, 43 (10): 972-80.
|
| [19] |
Takiuchi H, Fukuda H, Boku N, et al. Randomized phaseⅡ study of best-available 5-fluorouracil (5-Fu) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-fu-containing regimens (JCOG0407)[C]. American：J Clin Oncol, 2010, 28(15).
|
| [20] |
Narahara H, Iishi H, Imamura H, et al. Randomized phaseⅢ study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)[J]. Gastric Cancer, 2011,14(1): 72-80.
|
| [21] |
Kodera Y, Imano M, Yoshikawa T, et al. A randomized phase Ⅱ trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (inpact trial)[J]. Jpn J Clin Oncol, 2011, 41(2): 283-6.
|
| [22] |
Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier[J]. Cancer Treat Res, 1996, 82：53-63.
|
| [23] |
Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics[J]. Clin Pharmacokinet, 20 12, 51(4): 203-24.
|
| [24] |
Fushida S, Kinoshita J, Kaji M, et al. Phase Ⅰ/Ⅱ study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis[J]. Cancer Chemother Pharmacol, 20 13, 71(5): 1265-72.
|
| [25] |
Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination[J]. J Surg Oncol, 2012, 105(1): 38-42.
|
| [26] |
Kyle AH, Huxham LA, Yeoman DM, et al. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors [J] Clin Cancer Res, 2007, 13(9): 2804-10.
|
| [27] |
Los G, Mutsaers PH, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum(Ⅱ) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy[J]. Cancer Res, 1989, 49(12): 3380-4.
|
| [28] |
Pretorius RG, Petrilli ES, Kean CK, et al. Comparison of the iv. and ip. routes of administration of cisplatin in dogs[J]. Cancer Treat Rep, 1981, 65(11-12): 1055-62.
|
| [29] |
Hallissey MT, Allum WH, Roginski C, et al. Palliative surgery for gastric cancer[J]. Cancer, 1988, 62(2): 440-4.
|
| [30] |
Lasithiotakis K, Antoniou SA, Antoniou GA, et al. Gastrectomy for stage Ⅳ gastric cancer. a systematic review and meta-analysis [J] Anticancer Res, 2014, 34(5): 2079-85.
|
| [31] |
Spratt JS, Adcock RA, Sherrill W, et al. Hyperthermic peritoneal perfusion system in canines[J]. Cancer Res, 1980, 40(2): 253-5.
|
| [32] |
Liu X, Cai H, Sheng W, et al. Long-term results and prognostic factors of gastric cancer patients with microscopic peritoneal carcinomatosis[J]. PLoS One, 2012, 7(5): e37284.
|
| [33] |
He MM, Zhang DS, Wang F, et al. The role of non-curative surgery in incurable, asymptomatic advanced gastric cancer[J]. PloS One, 2013, 8(12): e83921.
|
| [34] |
Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy[J]. Ann Surg Oncol, 2010, 17(9): 23 70-7.
|
| [35] |
Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (hipec) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the gymssa trial[J]. J Surg Oncol, 2014, 110(3): 275-84.
|
| [36] |
Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phaseⅢ randomized clinical trial[J]. Ann Surg Oncol, 20 11, 18(6): 1575-81.
|
| [37] |
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010, 376(9742): 687-97.
|
| [38] |
mano M, Satou T, Itoh T, et al. Peritoneal metastatic lesions of gastric cancer exhibit low expression of human epidermal growth factor receptor 2[J]. Target Oncol, 2012, 7(4): 213-6.
|
| [39] |
Imano M, Itoh T, Satou T, et al. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer[J]. Target Oncol, 2013, 8(4): 231-5.
|
| [40] |
Bokemeyer C, Ridwelski K, Atanackovic D, et al. 2-year followup of a phase Ⅱ study on catumaxomab as part of a multimodal approach in primarily resectable gastric cancer[C]. England: Ann Oncol, 2012, 23: 228.
|
| [41] |
Heiss MM, Murawa P, Koralewski P, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase Ⅱ /Ⅲ trial [J]. Int J Cancer, 2010, 127(9): 2209-21.
|
| [42] |
Goéré D, Gras-Chaput N, Aupérin A, et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab[J]. BMC Cancer, 2014, 14: 148.
|
下载:
